Panmure Gordon Reiterates IMI (IMIAF) Buy Recommendation

Panmure Gordon reiterated a Buy on IMI (OTCPK:IMIAF) on November 25, 2025, with the average one‑year analyst price target reported at $26.71 (as of March 27, 2023), implying ~10.16% upside versus the last close of $24.25. Company projections show annual revenue of $2,237MM (up 1.54%) and projected non‑GAAP EPS of 1.17; institutional ownership is concentrated in 25 funds (down one owner, -3.85% quarter), with total institutional shares falling 4.34% to 14,504K. Major holders include Vanguard funds (VGTSX 3,643K, VTMGX 2,255K, VTRIX 2,186K), reflecting mixed positioning despite the analyst bullishness.

Analysis

Market structure: A reiterated Buy with only ~10% consensus upside signals modest positive momentum for IMIAF (IMI plc ADR) rather than a structural rerate. Winners are aftermarket/service-heavy industrials and UK exporters if sterling stabilizes; losers are high-capex OEM peers facing order delays. Small projected revenue growth (+1.5%) implies demand is steady not booming, preserving pricing power but limiting upside beyond 10–15% absent margin expansion.

Risk assessment: Key tail risks are a sharp UK infrastructure spending cut or a >€100m contract loss that could knock 15–30% off EBITDA, and a sterling move of ±5% that would shift reported USD EPS by roughly ±2–4%. Near-term (days–weeks) volatility will be driven by earnings/cash-flow beats or misses; medium-term (3–12 months) impact hinges on margin recovery and service revenue mix; long-term depends on product innovation and M&A execution. Hidden dependency: index/institutional reweights (Vanguard moves) can create transient selling unrelated to fundamentals.

Trade implications: Direct: build a tactical 2–3% long in IMIAF on weakness (buy zone $21–23), target $30 (≈+24%) over 6–12 months, stop-loss $22 or on a >200bp adverse margin revision. Pair: long IMIAF vs short Flowserve (FLS) sized 1:1 to isolate UK/FX vs global operational performance; expect relative outperformance if service revenue holds. Options: prefer LSE-listed IMI (IMI.L) options for liquidity; consider selling cash-secured $22 puts 6–9 months out for yield if implied vol > historical, or buying 9–12 month $28 calls for asymmetric upside if vol is depressed.

Contrarian angles: Consensus underestimates the impact of recurring service revenue and aftermarket pricing – a 200–300bp margin recovery would convert modest revenue growth into double-digit EPS upside, making the 10% target conservative. Conversely, the market may be overstating the hit from institutional share count declines (4.3% drop), which look like index tweaks; a temporary oversell on that thesis is a buying opportunity. Watch for dividend/buyback signals post-results as a catalyst that the market currently discounts.

Key Decisions for Investors

• Establish a 2–3% long position in IMIAF (OTC) on pullback into $21–23, target $30 within 6–12 months, set hard stop-loss at $22 or on any guidance downgrade >5% EPS cut.
• Execute a relative-value pair: go long IMIAF (2% portfolio) and short Flowserve (FLS) (1.5% portfolio) to hedge macro/cyclic exposure; close if IMIAF underperforms FLS by >10% in 3 months or if IMI issues positive buyback guidance.
• If option liquidity on IMI.L is sufficient, sell cash-secured $22 puts expiring 6–9 months out for income if premium ≥4% annualized yield; otherwise buy 9–12 month $28 calls sized to 0.5–1% portfolio for leveraged upside if IV <30%.
• Reduce exposure to pure OEM industrial names lacking aftermarket revenue by 2–4% in favor of service-heavy engineers (additions: IMIAF/IMI.L or Spirax-Sarco SPX.L) ahead of UK PMI releases and IMI quarterly results in next 30–90 days.